The rating and price target are based on the firm's new and preliminary model. VRX market capitalization is $9.29B with 22000 employees. Post opening the session at $27.24, the shares hit an intraday low of $26.77 and an intraday high of $27.45 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red. The previous close of the stock was seen at $89.17.
Currently Valeant Pharmaceuticals International, Inc.
In 2015, Valeant made headlines when it purchased two high-profile drugs, Isuprel and Nitropress, then subsequently raised their prices by several hundred percent. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was released by: Investorplace.com and their article: "Why Gilead Sciences, Inc".
On 21 Oct 2016, Farmer Ronald Harold (Director) bought 1500 shares at per share price of $181.6 with total value of $272395. Combining all the ratings on Valeant Pharmaceuticals International, Inc. Analysts have a mean recommendation of 2.90 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). (MRK) on September 7, 2016 announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company's anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of December 24, 2016. One Month Ago, the stock has been recommended as "Buy" from 5 and 3 suggested "Sell" for the stock. For the next 5 years, Valeant Pharmaceuticals International, Inc.is expecting Growth of 11.07% per annum, whereas in the past 5 years the growth was 24.31% per annum. A research note issued on 6/23/2016 the stock was downgraded by JP Morgan from Overweight to Neutral. They last posted EPS of $1.4 for the quarter ending 2016-06-30. Mean recommendation on this stock is 2.40.
Historically, if we look at price target revisions, three weeks ago Valeant Pharmaceuticals Intl Inc (NYSE:VRX)'s price target was revised on 08/22/16 by the analysts, however the bullish price estimates of the stock set at $81.00 while the bearish estimates kept at $22.00 over the next one year. The highest achievable sales estimated by the analysts are $2,682.80M while lowest reachable sales target of $2,525.40M calculated by analysts. The stock has been given a mean "HOLD" rating after the consensus analysis of "9" Analysts.
"Hospital representatives who were quoted in press reports that they are "paying the same high price" are likely not taking end of quarter rebates into account", Valeant said. The sales consensus among polled analysts prior to the last earnings announcement was $ 2,459.55M. The gap between the estimate and actual number was $-0.19 which created a surprise factor of -11.95%. Top-level EPS estimate is set at $1.95 while low-level EPS estimate among analysts is focused at $1.65.